Advertisement


Ana Oaknin, MD, PhD, on Cervical Cancer: Safety and Efficacy Results With Nivolumab and Ipilimumab

ESMO Congress 2022

Advertisement

Ana Oaknin, MD, PhD, of Barcelona’s Vall d’Hebron University Hospital, discusses findings from the CheckMate 358 trial, which showed that chemotherapy-free immunotherapy with nivolumab alone or in combination with ipilimumab may provide durable tumor regression with manageable toxicity in patients with recurrent or metastatic cervical cancer, regardless of tumor PD-L1 expression (Abstract 520MO).

 



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
CheckMate 358 is an ongoing Phase I/II study analyzing the role of nivolumab and nivolumab/ipilimumab combination in virus-associated cancer, including cervical cancer, regardless of PDL1 status. In the cervical cancer cohort, recovering metastatic cervical cancer patients were randomized into two arms, nivolumab plus ipilimumab in two different regimens: NIVO 1 IPI 3, or NIVI 3 IPI 1. These combinations were analyzed in the first-line setting and the second-line. The primary objective of the study was overall response rate and secondary objective progression-free survival, overall survival, and duration of response. The two-treatment combination show promising overall response rate, and remarkably, we observe greater responses when the patient received this combination of first-line therapy. Interestingly, the combination show responses regardless of PDL1 status. And when we saw the response rate in this combination were greater that we saw with nivolumab monotherapy. In addition, PFS and overall survival were really, really promising. When we look at the median overall survival for those patients treated with NIVO 1 IPI 3, was around 20 months and interestingly 48% of the patients were alive up to NGS. However, this data should be interpreted with caution because the trial is not fully randomized and the population was a mixed population. The safety profile of the combination in this study was aligned with the previous reported data. We need to say that some adverse events, such as hepatitis and colitis seem to be higher for those patients treated with nivolumab 1 ipilimumab 3. But in conclusion, I can say that outcome from the NIVO 3 combination show very, very promising outcome, and it may be considered as a kind of chemotherapy free regimen for our patient with metastatic recurrent cervical cancer.

Related Videos

Colorectal Cancer
Immunotherapy

Julien Taïeb, MD, PhD, on Colorectal Cancer: Recent Findings on Avelumab vs Standard Second-Line Chemotherapy

Julien Taïeb, MD, PhD, of Paris Descartes University, discusses phase II results from the SAMCO-PRODIGE 54 trial, which shows the efficacy and safety of avelumab in the second-line treatment of patients with deficient DNA mismatch–repair microsatellite-instability metastatic colorectal cancer. According to Dr. Taïeb, the study indirectly suggests this population should be treated as soon as possible with an immune checkpoint inhibitor (Abstract LBA23).

Breast Cancer

Matthew P. Goetz, MD, on Breast Cancer: Interim Survival Results With Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor

Matthew P. Goetz, MD, of Mayo Clinic, discusses recent data from the MONARCH 3 trial of patients with advanced hormone receptor–positive, HER2-negative breast cancer. The study, a second interim analysis, showed that longer overall survival was observed in both the intention-to-treat group as well as in the subgroup with visceral disease. However, neither met the threshold for statistical significance, and further analyses are planned when more data can be reported. (Abstract LBA15).

Kidney Cancer

Nizar M. Tannir, MD, on RCC: Data on Bempegaldesleukin Plus Nivolumab vs Tyrosine Kinase Inhibitors in Untreated Disease

Nizar M. Tannir, MD, of The University of Texas MD Anderson Cancer Center, discusses phase III findings from the PIVOT-09 study, which compared bempegaldesleukin plus nivolumab with the investigator’s choice of a tyrosine kinase inhibitor (either sunitinib or cabozantinib) in patients with previously untreated advanced renal cell carcinoma (Abstract LBA68).

Lung Cancer
Immunotherapy

Martin Reck, MD, PhD, on NSCLC: New Findings on Cemiplimab, Nivolumab, and Ipilimumab

Martin Reck, MD, PhD, of Germany’s Lung Clinic Grosshansdorf, details two trials that included patients with advanced non–small cell lung cancer: 3-year survival outcomes in the EMPOWER-Lung 1 study of continued cemiplimab-rwlc beyond disease progression with the addition of chemotherapy, and phase III results from the IFCT-1701 trial of nivolumab plus ipilimumab 6-month treatment vs treatment continuation (LBA54 and Abstract 972O).

Kidney Cancer

Thomas Powles, MD, PhD, and Christopher Sweeney, MBBS, on RCC: Expert Review of Two Key Studies on Atezolizumab, Nivolumab, and Ipilimumab

Thomas Powles, MD, PhD, of Barts Health NHS Trust, Queen Mary University of London, and Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, discuss two important phase III studies on renal cell cancer (RCC) presented at ESMO 2022: IMmotion010, which examined the efficacy and safety of atezolizumab vs placebo as adjuvant therapy in patients with RCC at increased risk of recurrence after nephrectomy; and CheckMate 914, which compared nivolumab monotherapy or nivolumab combined with ipilimumab vs placebo in patients with localized disease who underwent radical or partial nephrectomy and who are at high risk of relapse. (Abstract LBA4 & LBA66).

Advertisement

Advertisement




Advertisement